ImmunityBio Inc., a prominent immunotherapy company, has announced early findings from its QUILT-106 Phase I trial. The study is investigating the safety and preliminary efficacy of a novel CD19 CAR-NK therapy, used alone and in combination with rituximab, for patients with relapsed or refractory CD19⁺CD20⁺ B-cell non-Hodgkin lymphoma (NHL). This trial is significant given the challenging nature of treating this disease, particularly Waldenstrom macroglobulinemia $(WM)$, which is considered incurable with existing treatments. In the trial, two heavily pretreated patients with WM demonstrated promising complete responses without chemotherapy lymphodepletion. Both patients tolerated the treatment well, with no significant toxicities reported. One patient achieved complete remission with CD19 CAR-NK monotherapy, while the other achieved remission with the combination therapy. The responses have been maintained for six months. These preliminary findings have been submitted for presentation at the upcoming American Society of Hematology annual meeting. Recruitment continues to further validate these results and explore this chemotherapy-free approach as a potential treatment option for relapsed WM.